An age adjusted comorbidity index to predict long-term, other cause mortality in men with prostate cancer

Journal of Urology

Volumn 194, Issue 1, 2015, Pages 73-78

  Daskivich, Timothy J ^a,c   Kwan, Lorna ^a   Dash, Atreya ^d   Saigal, Christopher ^a,c   Litwin, Mark S ^b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c VETERANS AFFAIRS MEDICAL CENTER   (United States)

^d UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

Author keywords

comorbidity; mortality; nomograms; outcome assessment (health care); prostatic neoplasms

Indexed keywords

AGED; CANCER MORTALITY; CANCER STAGING; COHORT ANALYSIS; COMORBIDITY; GENITAL SYSTEM DISEASE ASSESSMENT; GROUPS BY AGE; HUMAN; INCIDENCE; LONG TERM CARE; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATE CANCER SPECIFIC COMORBIDITY INDEX; REVIEW; AGE; CAUSE OF DEATH; MIDDLE AGED; MORTALITY; PROGNOSIS; PROSTATIC NEOPLASMS; TIME;

AGE FACTORS; AGED; CAUSE OF DEATH; COMORBIDITY; HUMANS; MALE; MIDDLE AGED; PROGNOSIS; PROSTATIC NEOPLASMS; TIME FACTORS;

EID: 84940639918     PISSN: 00225347     EISSN: 15273792     Source Type: Journal    
DOI: 10.1016/j.juro.2015.01.081     Document Type: Article

References (25)

1. A. Bill-Axelson, L. Holmberg, M. Ruutu, and et al. Radical prostatectomy versus watchful waiting in early prostate cancer. SPCG-4 Investigators N Engl J Med 364 2011 1708
2. A. Bill-Axelson, L. Holmberg, M. Ruutu, and et al. Radical prostatectomy versus watchful waiting in early prostate cancer N Engl J Med 352 2005 1977
3. T.J. Daskivich, F. Kang-Hsien, T. Koyama, and et al. Impact of age, tumor risk, and comorbidity on competing risks for survival in a U.S. population-based cohort of men with prostate cancer Ann Intern Med 158 2013 709
4. A. Berglund, H. Garmo, C. Tishelman, and et al. Comorbidity, treatment and mortality: a population based cohort study of prostate cancer in PCBaSe Sweden J Urol 18 2011 833
5. P.C. Albertsen, D.F. Moore, W. Shih, and et al. Impact of comorbidity on survival among men with localized prostate cancer J Clin Oncol 29 2011 1335
6. M.J. Resnick, T. Koyama, K.H. Fan, and et al. Long-term functional outcomes after treatment for localized prostate cancer N Engl J Med 368 2013 436
7. T.J. Daskivich, K. Chamie, L. Kwan, and et al. Overtreatment of men with low-risk prostate cancer and significant comorbidity Cancer 117 2011 2058
8. C.B. Roberts, P.C. Albertsen, Y.H. Shao, and et al. Patterns and correlates of prostate cancer treatment in older men Am J Med 124 2011 235
9. T.J. Daskivich, K. Chamie, L. Kwan, and et al. Improved prediction of long-term, other-cause mortality in men with prostate cancer J Urol 186 2011 1868
10. M.E. Charlson, P. Pompei, K.L. Ales, and et al. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation J Chronic Dis 40 1987 373
11. J.P. Fine, and R.J. Gray A proportional hazards model for the subdistribution of a competing risk J Am Stat Assoc 94 1999 496
12. A.B. Mariotto, Z. Wang, C.N. Klabunde, and et al. Life Tables adjusted for comorbidity more accurately estimate noncancer survival for recently diagnosed cancer patients J Clin Epidemiol 66 2013 1376
13. H. Cho, C.N. Klabunde, R. Yabroff, and et al. Comorbidity-adjusted life expectancy: a new tool to inform recommendations for optimal screening strategies Ann Intern Med 159 2013 667
14. Daskivich TJ, Kwan L, Dash A, et al. Less is more: comorbidity count vs. Charlson score to predict long-term, other-cause mortality in men with early-stage prostate cancer. Unpublished data.
15. I. Thompson, J.B. Thrasher, G. Aus, and et al. Guideline for the management of clinically localized prostate cancer: 2007 update J Urol 177 2007 2106
16. J. Mohler, R.R. Bahnson, B. Boston, and et al. NCCN clinical practice guidelines in oncology: prostate cancer J Natl Compr Canc Netw 8 2010 162
17. A. Heidenreich, J. Bellmunt, M. Bolla, and et al. EAU Guidelines on Prostate Cancer. Part 1: screening, diagnosis, and treatment of clinically localized disease Eur Urol 59 2011 61
18. J. Walz, N. Suardi, S.F. Shariat, and et al. Accuracy of life tables in predicting overall survival in patients after radical prostatectomy BJU Int 102 2008 33
19. P.K. Han, W.M. Klein, T.C. Lehman, and et al. Laypersons' responses to the communication of uncertainty regarding cancer risk estimates Med Decis Making 29 2009 391
20. T.J. Daskivich, J. Lai, A.W. Dick, and et al. Comparative effectiveness of aggressive versus non-aggressive treatment for men with early-stage prostate cancer and differing comorbid disease burdens at diagnosis. Urologic Diseases in America Project Cancer 120 2014 2432
21. L. Klotz, L. Zhang, A. Lam, and et al. Clinical results of long-term follow-up of a large, active surveillance cohort with localized prostate cancer J Clin Oncol 28 2010 126
22. G.L. Lu-Yao, P.C. Albertsen, and D.F. Moore Outcomes of localized prostate cancer following conservative management JAMA 302 2009 1202
23. S. Loeb, E.M. Schaeffer, B.J. Trock, and et al. What are the outcomes of radical prostatectomy for high-risk prostate cancer? Urology 76 2010 710
24. M. Spahn, C. Weiss, P. Bader, and et al. Long-term outcome of patients with high-risk prostate cancer following radical prostatectomy and stage-dependent adjuvant androgen deprivation Urol Int 84 2010 164
25. P.C. Albertsen, D.G. Fryback, B.E. Storer, and et al. The impact of co-morbidity on life expectancy among men with localized prostate cancer J Urol 156 1996 127